-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target

Benzinga·11/18/2025 19:30:54
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.